Bill Taranto

I think those kind of things would help us more.

And that's kind of what we think about is, you know, how to how to some of the lobbying groups help push forward digital and technology faster approving of patients.

medical device technologies.

Now, I don't invest in that, but that would help quite a bit.

Monitoring devices, all these things that get coded properly and can get reimbursed.

All those type of things would then help our investment community, I think, much better.

But we don't spend much time on those broader problems that pharma's trying to solve.

That's for Merck to think about and how they want to solve those things.

We don't really get involved in those kind of areas or think about them much because it doesn't really have a direct impact

Yeah, I think if you think of sort of the large potential areas in the future, infrastructure platforms, you know, at a high level, systems that serve large-scale clinical R&D supply chain and patient access needs.

And I think more specifically, we're still very bullish because it's still, again, very early, the drug discovery and development, the AI and ML drug discovery.

I think you mentioned it, the clinical trial development is going to be big for us as well as we think about

management, patient recruitment, decentralized trials, retention, even after recruitment.

Supply chain is, I think it's one of, again, one of the most underlooked at areas of pharma services, but every pharma has the same issues and are struggling with it.

So I think around supply chain and logistics and that control tower idea where we have real-time supply chain intelligence, cold chain,

Delivery, distribution, global medicine logistics.

I think that's going to be really important as we try to give access on a more global basis.

And I think patient access, you know, I think you sound really direct.

You know, Merck doesn't have any really of those consumer type drugs that we can go direct.

But I think that shows you.